



JPW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/779890	
	Filing Date	February 17, 2004	
	First Named Inventor	Stephen Shaughnessy	
	Art Unit	1646	
	Examiner Name	E. Kemmerer	
Total Number of Pages in This Submission	9	Attorney Docket Number	MDSP-P04-180

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): - 16 Cited non-US patent references not provided before (CB, CF, CG, CL, CN, CP, CQ, CS-CY, CA1, and CB1) - Copy of International Search Report (ISR) in PCT/CA99/00516 (3 pages) - Certificate of Mailing under 37 C.F.R. 1.8 (1 page) - Return Receipt Postcard
<div>Remarks</div>		


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	ROPES & GRAY LLP		
Signature			
Printed name	Yu Lu, Ph.D.		
Date	September 13, 2005	Reg. No.	50,306

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: 9/13/05	Signature: (Susan Lanney)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 9/13/05 Signature: 
(Susan Lanney)

Docket No.: MDSP-P04-180
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Shaughnessy *et al.*

Application No.:	10/779890	Confirmation No.:	1480
Filed:	February 17, 2004	Art Unit:	1646
For:	OSTEOPOROSIS TREATMENT	Examiner:	E. Kemmerer

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 C.F.R. § 1.97(b)(3)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 C.F.R. § 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 C.F.R. § 1.98(a)(2).

Those documents which are marked with a double asterisk (**) next to the Cite No. in the attached form PTO/SB/08 are not supplied because they were previously cited by or

submitted to the Office in a prior application number 09/715838, filed on November 17, 2000, and relied upon in this application for an earlier filing date under 35 U.S.C. § 120.

A copy of the International Search Report (ISR) in a related PCT application PCT/CA99/00516 is also enclosed.


In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists. In accordance with 37 C.F.R. § 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 C.F.R. § 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. **18-1945**, under Order No. **MDSP-P04-180**.

Dated: September 13, 2005

Respectfully submitted,

By 
Yu Lu, Ph.D.

Registration No.: 50,306
Fish & Neave IP Group
ROPES & GRAY LLP
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7000
(617) 951-7050 (Fax)
Attorneys/Agents For Applicant



PTO/SB/08a/b (07-05)
 Approved for use through 07/31/2006. OMB 0651-0031
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/779890
				Filing Date	February 17, 2004
				First Named Inventor	Stephen Shaughnessy
				Art Unit	1646
				Examiner Name	E. Kemmerer
Sheet	1	of	2	Attorney Docket Number	MDSP-P04-180

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-4,683,195-A	07-28-1987	Mullis et al.	
	AB*	US-5,215,895-A	06-01-1993	Bennett et al.	
	AC*	US-5,270,181-A	12-14-1993	McCoy et al.	
	AD*	US-5,292,646-A	03-08-1994	McCoy et al.	
	AE*	US-5,530,101-A	06-25-1996	Queen et al.	
	AF*	US-5,849,283-A	12-15-1998	Ciliberto et al.	
	AG*	US-5,888,510-A	03-30-1999	Kishimoto et al.	
	AH*	US-5,914,106-A	06-22-1999	Ciliberto et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA**	CA-2177837	06-07-1996	ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A.		
	BB**	WO-96/18648	06-20-1996	ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A.		
	BC**	WO-96/19574	06-27-1996	GENETICS INSTITUTE, INC.		
	BD**	WO-98/15283	04-16-1998	IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE		
	BE**	WO-99/59608	11-25-1999	HAMILTON CIVIC HOSPITAL RESEARCH DEVELOPMENT CORPORATION		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA**	AUSTIN et al., Site-directed mutagenesis of alanine-382 of human antithrombin III. FEBS Letters 280 (2): 254-258, 1991.	
	CB	CURTIS et al., Blood 90(11): 4403-4412, 1997.	
	CC**	DAVIS et al., LIFR.beta. and gp130 as Heterodimerizing Signal Transducers of the Tripartite CNTF Receptor, Science 260: 1805-1808, 1993.	
	CD**	ERSHIER et al., Immunologic Aspects of Osteoporosis, Devel. Compar. Immunol. 21 (6): 487-499, 1997.	
	CE**	GIRASOLE et al., Interleukin-11: A New Cytokine Critical for Osteoclast Developments, J. Clin. Invest. 93: 1516-1524, 1994.	
	CF	HILL et al., Endocrinology 139(4): 1564-1572, 1998.	
	CG	HILTON et al., The EMBO Journal 13(20): 4765-4775, 1994.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/779890
				Filing Date	February 17, 2004
				First Named Inventor	Stephen Shaughnessy
				Art Unit	1646
				Examiner Name	E. Kemmerer
Sheet	2	of	2	Attorney Docket Number	MDSP-P04-180

CH**	ISHIMI et al., IL-6 is Produced by Osteoblasts and Indices Bone Resorption. J. Immunol. 145 (10): 3297-3303, 1990.
CI**	KAROW et al., Mediation of interleukin-11-dependent biological responses by a soluble form of the interleukin-11 receptor. Biochem J. 318: 489-495, 1996.
CJ**	KIM et al., Involvement of Different Second Messengers in Parathyroid Hormone- and Interleukin-1-Induced Interleukin-6 and Interleukin-11 Production in Human Marrow Stromal cells. J. Bone Miner. Res. 12 (6): 896-902, 1997.
CK**	LEAHY et al., A Method for Attachment of Peptides to a Solid Surface with Enhanced Immunoreactivity. Biotechniques 13 (5): 738-743, 1992.
CL	MANOLAGAS et al., Ciba Foundation Symposium, pp.187-202, 1995.
CM**	MICHALON et al., Enzyme Coupling Method on Calibrated Nylon Spheres: Application to the Selective Trypsinization of Histones in Chromatin. Biochem. Biophys. Res. Comm. 167 (1): 9-15, 1990.
CN	MUIR et al., Blood 88(4): 1314, 1996.
CO**	MUIR et al., A Histomorphometric Comparison of the Effects of Heparin and Low-Molecular-Weight Heparin on Cancerous Bones in Rats. Blood 89 (9): 3236-3242, 1997.
CP	MUSASHI et al., PNAS 88: 765, 1991.
CQ	NANDURKAR et al., Blood 90(6): 2148, 1997.
CR**	NGO et al., 1994, The Protein Folding Problem and tertiary Structure Prediction, Merz et al., eds., Birkhauser, Boston, pp. 491-495.
CS	POLI et al., The EMBO Journal 13(5): 1189, 1994.
CT	ROBB et al., Nature Medicine 4(3): 303-308, 1998.
CU	ROMAS et al., Journal of Experimental Medicine 183(6): 2581-2591, 1996.
CV	TAMARU et al., PNAS 90: 11924, 1993.
CW	TERAMURA et al., Blood 79: 327, 1992.
CX	VAN LEUVEN et al., Genomics 31(1): 65, 1996.
CY	VLASSELAER, Progress in Growth Factor Research 4: 337, 1992.
CZ**	WELLS, Biochemistry 29: 8509-8517, 1990.
CA1	WHITEHORN et al., Biotechnology 13(11): 1215, 1995.
CB1	YIN et al., The Journal of Immunology 151(5): 2555, 1993.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



Application No. (if known): 10/779890


Attorney Docket No.: MDSP-P04-180

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on September 13, 2005
Date


Signature

Susan Lanney

Typed or printed name of person signing Certificate

Registration Number, if applicable

(617) 951-7000
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal (1 page)
Information Disclosure Statement (2 pages)
IDS (Citation) by Applicant (41 References) (2 pages)
16 Cited non-US patent references not provided before (CB, CF, CG, CL,
CN, CP, CQ, CS-CY, CA1, and CB1)
Copy of International Search Report (ISR) in PCT/CA99/00516 (3 pages)